Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Cidara To Take Rezafungin Into Phase III In Two Severe Infection Indications

Infectious disease

Related Content

Cidara CEO Stein brings Trius gang, biotech vets together

Jul 01 2014

BIO Notebook, Day 3: Lilly Expands R&D Site, Sigilon Raises Cash And CytomX Talks Deal Strategy

Jun 22 2017

Pipeline Watch: Phase III Read-Outs For Ozanimod, Olaparib And Sapacitabine

Feb 27 2017

Related Companies

Cidara Therapeutics, Inc.

Merck & Co., Inc.

Astellas Pharma, Inc.

Trius Therapeutics, Inc.

Additional Topics

Research & Development Clinical Trials Companies Drug Approval Standards Rare Diseases Infectious Diseases BioPharmaceutical

More from R&D

More from Scrip

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window